Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
222.08
-4.58 (-2.02%)
At close: Apr 28, 2026, 4:00 PM EDT
222.15
+0.07 (0.03%)
After-hours: Apr 28, 2026, 5:54 PM EDT
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Ascendis Pharma stock have an average target of 281.5, with a low estimate of 250 and a high estimate of 342. The average target predicts an increase of 26.76% from the current stock price of 222.08.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock from 16 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 9 | 9 | 10 | 10 | 10 | 10 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 16 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $262 → $292 | Strong Buy | Maintains | $262 → $292 | +31.48% | Apr 16, 2026 |
| Wedbush | Wedbush | Buy Reiterates $273 | Buy | Reiterates | $273 | +22.93% | Apr 9, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $252 → $290 | Strong Buy | Initiates | $252 → $290 | +30.58% | Mar 16, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $250 → $275 | Buy | Maintains | $250 → $275 | +23.83% | Mar 3, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $246 → $262 | Buy | Maintains | $246 → $262 | +17.98% | Feb 12, 2026 |
Financial Forecast
Revenue This Year
1.41B
from 720.13M
Increased by 96.35%
Revenue Next Year
2.05B
from 1.41B
Increased by 44.91%
EPS This Year
4.45
from -3.76
EPS Next Year
10.98
from 4.45
Increased by 146.99%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.6B | 2.5B | ||||||
| Avg | 1.4B | 2.0B | ||||||
| Low | 1.3B | 1.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 122.6% | 75.9% | ||||||
| Avg | 96.4% | 44.9% | ||||||
| Low | 73.6% | 14.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 6.20 | 18.13 | ||||||
| Avg | 4.45 | 10.98 | ||||||
| Low | 1.84 | 5.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 307.9% | ||||||
| Avg | - | 147.0% | ||||||
| Low | - | 12.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.